Articles |
From the Departments of Internal Medicine, Pathology, Biological Chemistry, and Physiology, Cardiovascular Research Center, Howard Hughes Medical Institute, University of Michigan, Ann Arbor.
Correspondence to Elizabeth G. Nabel, MD, Cardiovascular Research Center, University of Michigan, MSRB III, Room 7301, 1150 W Medical Center Dr, Ann Arbor, MI 48109-0644. E-mail enabel@umich.edu.
| Abstract |
|---|
|
|
|---|
Key Words: PDGF B gene cell proliferation gene transfer gene expression neointima
| Introduction |
|---|
|
|
|---|
The delivery of recombinant genes into vascular cells at specific sites in the circulation permits the systematic analysis of gene function in the arterial wall in vivo. Previous studies from our laboratory suggest that the introduction of a PDGF B gene in porcine arteries promotes formation of a neointima de novo.9 These observations and findings of Jawien and coworkers5 and Ferns and colleagues10 , which demonstrate that the infusion of a polyclonal PDGF antibody inhibits development of an intimal lesion, provide evidence that this growth factor contributes to intimal lesion formation in vivo. While these studies suggest that PDGF BB is associated with intimal thickening, the mechanisms responsible for development of the intima by PDGF B expression have not been defined. Accordingly, the goals of this study were to examine the pathogenesis of intimal thickening in PDGF B genetransfected arteries by analysis of smooth muscle cell proliferation and migration, extracellular matrix synthesis, and inflammatory cell infiltration.
| Methods |
|---|
|
|
|---|
In Vivo Gene Transfer
Direct gene transfer was performed in the right and left
iliofemoral arteries of 26 domestic Yorkshire pigs, 12 with a PDGF B
gene (pSV-PDGF B) and 14 with a reporter gene (pRSV-hpAP or pRSV-SA).
After sedation with telazol (6 mg/kg body wt) and xylazine (2.2 mg/kg),
the pigs were intubated and anesthetized with 1%
halothane. Under sterile surgical techniques, a double-balloon
catheter was inserted into the iliofemoral artery.18 The
arterial segment was rinsed with 5 mL saline solution and 5
mL Opti-MEM (GIBCO BRL) to clear the vessel of blood. DNA liposome
conjugates were prepared 10 minutes before the insertion of the
catheter by mixing 12 µg DOTMA/DOPE (1 mg/mL) in 0.2 mL Opti-MEM at
room temperature. Plasmid DNA (5 µg) (stock concentration >1 mg/mL)
was added to the liposomes and left at room temperature for 5 to 10
minutes. Opti-MEM (0.5 mL) was added to the DNA liposome solution, and
the complexes (0.7 mL) were instilled into the arterial
space between the two balloons for 20 minutes at 150 mm Hg pressure.
Previous studies from our laboratory demonstrated that direct gene
transfer into an artery at this pressure produces minimal
arterial injury.9 After gene delivery, the
catheter was removed, and arterial flow was restored.
Animals were killed 1, 2, 4, 7, 14, and 21 days after gene transfer. At
each time point, 4 pigs were studied: 2 experimental pigs transfected
with pSV-PDGF B (n=4 arteries) and 2 control pigs transfected with
pRSV-SA gene (n=4 arteries). When the pigs were killed, arteries were
serially sectioned into five rings in an identical manner. Sections 1,
3, 4, and 5 were fixed with 10% buffered formaldehyde or methyl
Carnoy's solution (60% methanol/30% ethanol/10% glacial acetic acid
[vol%]) and embedded in paraffin. Section 2 was rapidly frozen in
liquid nitrogen and stored at -80°C for DNA and RNA isolation.
Two additional pigs underwent gene transfer of pRSV-hpAP into the right
and left iliofemoral arteries (n=4 arteries), and these arteries were
analyzed for reporter gene expression 4 days later. All animal
studies were performed within the guidelines of the National Institutes
of Health and with the approval of the University of Michigan Committee
on the Use and Care of Animals.
Analysis of Gene Transfer and
Expression
The presence of recombinant PDGF B DNA from transfected vessels
was analyzed by PCR. Primers were synthesized from
v-sis sequence in regions not homologous to porcine PDGF
sequence to generate a 384-bp fragment: sense (25-mer), TCA TCC TCT TAA
GCT GCG TAT TCG G; antisense (25-mer), ACA CCA GGA AGT TGG CAT TGG TGC
G. Alkaline phosphatase gene transfer was analyzed by
oligonucleotide primers as follows: sense (30-mer), TGG
GGC CCT GCA TGC TGC TGC TGC TGC TGC; antisense (30-mer), TGG AAG TTG
CCC TTG ACC CCG CAC AGG TAG; and streptavidin gene: sense (25-mer), TTC
CCT GAC CAC GGT CTC GAT TAC G; antisense (25-mer), GCA GCC ACT GGG TGT
TGA TCC TCG C. Genomic DNA was prepared from arteries by proteinase K
digestion and phenol and chloroform extraction.19 The PCR
was performed with 100 ng genomic DNA for 35 cycles of denaturation
(94°C, 1 minute), annealing (60°C, 2 minutes), and polymerization
(72°C, 2 minutes) in an automated DNA thermal cycler (Perkins-Elmer
Cetus). Samples were analyzed by ethidium bromide staining in a
1% agarose gel. The sensitivity of the PCR analysis is
approximately one copy of recombinant gene per 105
genomes.
Expression of recombinant PDGF B RNA was detected by RT-PCR. Total cellular RNA was obtained from arterial samples by acid guanidinium isolation.20 Nucleic acids were extracted and treated with DNAase I (30 U, 10 U/µL) (RNase-free) (Boehringer Mannheim Biochemicals) in buffer (in mmol/L: Tris-HCl 40, pH 7.9, NaCl 10, MgCl2 6, and CaCl2 0.1) at 37°C for 30 minutes to eliminate contamination. Samples were analyzed in the presence or absence of reverse transcriptase, 15 U (Promega) with oligo (dT). Primers for PDGF B, alkaline phosphatase, and streptavidin sequence were generated as described. The PCR was performed with 35 cycles of denaturing, annealing, and polymerization as described. Positive and negative controls were performed with each PCR.
Histochemistry
Expression of recombinant hpAP protein was detected by
histochemical analysis of transfected arteries as
described.21 Briefly, formalin-fixed
paraffin-embedded specimens were sectioned and incubated in PBS at
65°C for 60 minutes to inactivate endogenous
alkaline phosphatase. Sections were incubated in PBS containing a
chromogenic substrate of 5-bromo-4-chloro-3-indolyl
phosphate p-toluidine (1 mg/mL) (GIBCO BRL) and nitro blue
tetrazolium chloride (1 mg/mL) (GIBCO BRL) for 19 hours. This substrate
yielded a dark purple stain in the presence of alkaline phosphatase.
Sections were rinsed with PBS and counterstained with methylene
green.
Immunohistochemistry
Immunohistochemical studies were performed with mAb to human
PDGF BB, smooth muscle
-actin, vWf, BrdC, type I procollagen,
porcine macrophages, and human CD3(+) lymphocytes. Serial
sections of methyl Carnoy or formalin-fixed,
paraffin-embedded arteries (6 µm) were placed onto
poly-L-lysinecoated slides, deparaffinized in three
changes of xylene, and rehydrated in 100%, 95%, and 75% ethyl
alcohol. Incubation in 0.3% hydrogen peroxide for 30 minutes exhausted
endogenous peroxidase activity. For each antibody, the
dilution that yielded optimal specific staining was determined in pilot
experiments.
Primary antibodies were diluted in PBS with 1% BSA and
applied to the slides for 1 hour. The following primary antibodies were
used: a monoclonal mouse anti-human PDGF BB IgG2b antibody, 1:400
dilution (Promega); a monoclonal mouse antismooth muscle
-actin antibody, 1:500 dilution (Boehringer Mannheim
Biochemical); a monoclonal goat anti-human vWf antibody, 1:10 000
dilution (Atlantic Antibodies); a monoclonal mouse anti-BrdC antibody,
1:1000 dilution (Amersham Life Sciences); a monoclonal SP1.d8
aminopeptide-specific type I procollagen antibody, 1:500 dilution
(Developmental Studies, Hybridoma Bank, University of Iowa); a
monoclonal 1912 carboxypeptidespecific type I procollagen
antibody, 1:1000 dilution (Chemicon International, Inc); a monoclonal
mouse anti-porcine macrophage IgG2b antibody, 1:100
dilution (ATCC HB 142.1, American Type Culture Collection); and a
monoclonal rabbit anti-human CD3 antibody, 1:100 dilution (DAKO).
The monoclonal mouse anti-human PDGF BB IgG2b antibody primarily
detects PDGF BB homodimer but potentially can stain human PDGF AB
heterodimer and AA homodimer and porcine PDGF. Control experiments were
performed using a purified mouse IgG2b antibody, 1:100 dilution
(Promega) or goat serum. These control first antibodies did not stain
the arterial specimens. After washes in 0.05 mol/L
Tris-buffered saline, a biotinylated secondary antibody, horse
anti-mouse IgG2 or horse anti-rabbit IgG2, 1:400 dilution
(Zymed Laboratories, Inc), was applied at room temperature for 30
minutes. Slides were developed with either a
streptavidinhorseradish peroxidase complex (Vector Laboratories)
or a Vectastain ABCalkaline phosphatase reagent (Vector
Laboratories). The streptavidinhorseradish peroxidase complex,
1:5000 dilution, was applied for 30 minutes at room temperature,
followed by a diaminobenzidine substrate (Sigma) in 0.045% nickel
chloride (room temperature, 10 minutes) to produce a gray-black
reaction and by counterstain with methyl green. Biotinylated
anti-mouse immunoglobulin, 1:200 dilution (Vector Laboratories),
was applied for 30 minutes, followed by another 30-minute incubation in
a Vectastain ABCalkaline phosphatase reagent (Vector Laboratories).
The substrate 3-amino-9-ethylcarbazole yields a red reaction
product, and sections were counterstained in methyl green.
Measurement of Cell Proliferation and
Morphometry
To determine the number of proliferating cells, arteries
were labeled with BrdC, and immunohistochemistry was performed. Animals
were injected with BrdC (25 mg/kg) 1 hour before they were killed.
Total nuclei and BrdC-positive nuclei were counted in the intima of
experimental and control arteries by a microscope-based video image
analysis system (Image One Systems, Universal Imaging Corp).
Eight high-power fields (magnification x400) were counted in four
sections from each artery. A proliferation index was calculated as the
ratio of labeled cells to total number of cells. The percentage
of intimal smooth muscle cells that were PDGF B positive was determined
from multiple sections of double-immunostained PDGF
Btransfected arteries by use of antibodies to smooth muscle
-actin and PDGF B. The numbers of positive cells per
high-power field were counted by the video imaging system. Eight
high-power fields were counted from four sections in each artery.
The percentage of PDGF B cells that were BrdC positive was measured in
a similar manner from sections double-immunostained
with antibodies to PDGF B and BrdC.
Measurements of intimal and medial thickness, area, and total cell number were determined on four sections from each artery by use of Image One Systems. Intimal and medial boundaries were determined by digital planimetry. Intimal and medial areas in each section were measured, and I/M area ratios from the four sections were averaged to derive an I/M area ratio for each artery.
Calculations of an expected-to-observed ratio of the number of intimal cells were made in PDGF arteries for days 1 through 21 after gene transfer. These calculations were based on BrdC proliferation indexes and assumed a cell doubling rate of 4 days in pig arteries.21
Statistical Analysis
Results are expressed as mean±SEM. Comparisons of
intimal thickness, I/M area ratio, number of intimal nuclei, BrdC
labeling index, number of nuclei per square micrometer,
percent procollagen-positive cells, and percent
trichrome-positive cells between PDGF B and control arteries were
made by a two-tailed, unpaired t test. Changes in
variables within experimental groups between time points were
examined by ANOVA with Dunnett's t test.22 23
A polynomial regression analysis was performed on intimal
smooth muscle cell numbers from days 1 through 21. Statistical
significance was assumed if a null hypothesis could be rejected at the
P=.05 level.
| Results |
|---|
|
|
|---|
-actin (Fig 1C
|
Transfected Arteries Express Recombinant PDGF B DNA, mRNA,
and Protein
To investigate the function of a PDGF B gene in porcine arteries
in vivo, a PDGF B expression plasmid was transfected into iliofemoral
arteries of 12 pigs by direct gene transfer. Twelve control pigs were
transfected with a plasmid expressing an S. avidini gene. To
examine the transfer of plasmid DNA in arteries, samples of PDGF B
genetransfected arteries were analyzed by PCR. PDGF B
plasmid was detected in PDGF B arteries 4 and 21 days (Fig 2A
, lanes 1
and 2) after gene transfer but not in S.
avidini genetransfected arteries at 4 days (Fig 2A
, lane 3).
To confirm expression of PDGF B, mRNA was analyzed by RT-PCR.
PDGF B RNA was detected in samples incubated with reverse transcriptase
but was not detected in its absence in transfected artery segments 4
and 21 days after gene transfer (Fig 2B
, lanes 1 through 4) compared
with S. avidini genetransfected arteries (Fig 2B
,
lanes 5 and 6). Transfer of plasmid DNA and mRNA expression were
confirmed in control arteries at similar time points (data not
shown).
|
To examine PDGF B protein expression, immunohistochemical studies were
performed with an mAb to human PDGF BB. Porcine arteries transfected
with a PDGF B gene demonstrated immunoreactive protein in the intima
and media (Fig 3C
through 3F), whereas PDGF B protein
was not detectable in the intima and media of control arteries (Fig 3A
). Immunoreactive protein was detected throughout the intima at 4
days (Fig 3C
and 3D
) and was observed predominantly in the luminal
region of the intima at 21 days (Fig 3E
and 3F
).
|
PDGF B Gene Expression Stimulates Intimal
Thickening
To determine the effect of PDGF B gene expression, transfected
arteries were analyzed by light microscopy at 1, 2, 4, 7, 14,
and 21 days after gene transfer. PDGF B gene expression was associated
with a significant increase in intimal thickness compared with control
arteries at 2 days (15.6±1.7 versus 6.4±0.5 µm) through 21
days (174.6±10.1 versus 19.4±1.9 µm) (P<.01 for
2, 4, 7, 14, and 21 days) (Fig 4A
). The I/M area ratio
was also significantly increased in PDGF arteries compared with control
arteries from 4 days (0.12±0.01 versus 0.05±0.01) through 21 days
(0.43±0.03 versus 0.07±0.01) (P<.01 for 4, 7, 14, and 21
days) (Fig 4B
). Fig 5
demonstrates
representative histology sections from PDGF B arteries
(Fig 5B
, 5D, 5F, 5H, 5J, 5L) compared with control arteries (Fig 5A
,
5C, 5E, 5G, 5I, 5K) at all time points after gene transfer. At 2 and 4
days, a two- to three-cell-layer intima was present in PDGF
B arteries (Fig 5D
and 5F
), and this intima thickened rapidly by 21
days (Fig 5L
). In contrast, a control artery at 21 days shows a small
layer of intimal cells (Fig 5K
).
|
|
PDGF B Gene Expression Is Associated With Intimal Smooth Muscle
Cell Proliferation
The intima of PDGF B arteries demonstrated a progressive
increase in the number of nuclei, from 174±8 at 1 day to 1618±265 at
7 days and 2263±280 at 21 days (P<.05, 1 day versus 4, 7,
14, and 21 days, ANOVA with Dunnett's t test) (Fig 6A
). There was a linear increase in intimal cells to day
7, but after day 7, the rate of cell accumulation reached a plateau
(R2=.87). The total number of cell nuclei
in the intima was up to threefold greater in PDGF B arteries compared
with control arteries at 7, 14, and 21 days (P<.01) (Fig 6A
). The increase in cell nuclei was paralleled in the first
week by an increase in cell proliferation. Cell proliferation was
observed in the intima of PDGF B arteries 24 hours after injury
(1.7±0.8% labeling index), was maximal at 7 days (7.5±1.0% versus
1.8±0.2%, control arteries, P<.01), but subsided at
day 14 (0.2±0.04%) (Fig 6B
). Double immunostaining
performed with mAbs to BrdC and smooth muscle
-actin identified
smooth muscle cells as the major proliferative cell type in the intima
(Fig 7A
through 7C).
|
|
To examine the role of PDGF BB in intimal cell proliferation,
double-label immunostaining with mAbs to PDGF BB,
BrdC, and smooth muscle
-actin was performed. The percentage of
smooth muscle cells expressing PDGF BB and the percentage of
PDGF-positive cells that were proliferating were measured with
the video image analysis system (Fig 7D
and 7E
). Seven days
after gene transfer, 33.8±7.9% of intimal smooth muscle cells were
PDGF B positive, and 8.8±2.1% were PDGF B positive at 21 days.
Intimal PDGF BB cells underwent proliferation: 10.3±1.7% of intimal
PDGF B cells were BrdC positive at 7 days compared with 4.5±0.6% at
21 days. This percentage of BrdC-positive cells, however, is higher
than the intimal BrdC labeling index at 7 (7.5±1.0%) and 21
(0.5±0.1%) days, suggesting a proliferative advantage to PDGF BB
cells. These studies suggest a correlation between PDGF expression and
intimal smooth muscle cell proliferation.
These observations suggested that PDGF B gene expression in porcine arteries was associated with early formation of an intima that progressed over a period of 3 weeks, compared with control arteries. Smooth muscle cells proliferated in the intima, peaking at 7 days. The total number of cells continued to increase in the intima from 7 to 21 days. To determine whether cell migration might contribute to the number of intimal cells during this time interval, an expected-to-observed ratio of intimal cells was calculated for PDGF arteries 1 to 21 days after gene transfer, based on BrdC labeling indexes. The expected-to-observed ratio was 0.51 at 2 days, 0.62 at 4 days, 0.42 at 7 days, 0.94 at 14 days, and 0.97 at 21 days. These data suggest that proliferation alone cannot account for the total number of observed intimal cells at 2 to 7 days, suggesting possible migration of cells into the intima. These observations are consistent with previous observations that PDGF BB stimulates migration of smooth muscle cells into the intima of injured arteries.5 10
PDGF B Gene Expression Is Associated With Extracellular Matrix
Synthesis After 14 Days
The number of nuclei in the intima of PDGF B arteries
progressively increased from 1 to 21 days. Cell density, expressed as
the number of nuclei per square micrometer, decreased in
the intima when the intimal area was greatest at 14 and 21 days (day 1,
0.18±0.01; day 4, 0.29±0.03; day 7, 0.36±0.04; day 14, 0.19±0.02;
day 21, 0.15±0.02) (Fig 8A
). This decrease in density
suggested that extracellular matrix deposition contributes to intimal
thickening. To investigate this hypothesis, we examined type I
procollagen synthesis and trichrome staining in PDGF B and control
arteries. The percentage of cells in PDGF B arteries that stained with
a type I procollagen antibody steadily increased from 1 day
(6.3±0.1%) to 7 days (10.1±0.8%), 14 days (14.3±1.3%), and 21
days (12.3±0.9%) (P<.05, 1 day versus 7, 14, and 21
days, ANOVA with Dunnett's t test [Fig 8B
]). Trichrome
staining in the intima of PDGF B arteries also progressively increased
from 1 day (1.2±0.2%) to 7 days (14.1±1.6%) and 14 days
(19.3±1.9%) and was greatest at 21 days (42.8±5.2%)
(P<.05, 1 day versus 7, 14, and 21 days, ANOVA with
Dunnett's t test), suggesting an accumulation of
extracellular matrix at later times (Fig 8C
). The absolute number of
cells that stained with a procollagen antibody was greater at 7, 14,
and 21 days in PDGF B arteries compared with control arteries
(P<.05) (Fig 8A
). These findings suggest that PDGF B gene
expression promotes intimal expansion that includes matrix deposition
at 2 and 3 weeks after gene transfer.
|
Lack of Inflammatory Cell Infiltration in the Intima and Effects of
PDGF B Gene Expression on the Media
Macrophages were observed in the intima at 1 and 2
days after gene transfer in both PDGF B and control arteries but at a
low frequency, two or fewer per high-power field (data not shown).
T cells were not observed in samples from PDGF B or control arteries
(data not shown). The medial cross-sectional area did not differ
significantly between PDGF B and control arteries at any time. No
significant increase in medial thickening was observed from 2 to 21
days after gene transfer in either group. Cell proliferation did not
change in the media between 1 and 21 days in PDGF B or control
arteries. These observations suggest that medial smooth muscle cells
did not undergo significant proliferation after transfection with a
PDGF B gene, and medial thickening was not present.
| Discussion |
|---|
|
|
|---|
The present findings suggest that PDGF B plays a major role in intimal lesion formation. Whether these effects are mediated directly or indirectly through autocrine or paracrine effects of PDGF BB is unknown. Evidence in support of a direct role for PDGF in smooth muscle cell accumulation includes mRNA studies showing that a PDGF B gene is expressed in porcine arteries for at least 3 weeks after gene transfer, and these same arteries developed intimal lesions, in contrast to control vessels in which intimal thickening was not observed. Double-labeling immunohistochemical studies show that smooth muscle cells that express PDGF BB undergo proliferation. In addition, it is possible that endogenous PDGF protein was produced in PDGF B genetransfected arteries in response to the recombinant gene. Previous control experiments for the effects of mechanical injury alone in balloon-injured nontransfected porcine arteries suggested that expression of endogenous PDGF protein was dependent on the severity of vessel injury,9 and PDGF BB protein was not detected in arteries transfected with pRSV-SA in this study. Finally, factors responsible for extracellular matrix accumulation, including TGF-ß, may be regulated in part by PDGF B expression. For example, TGF-ßinduced increases in smooth muscle cell proliferation and matrix synthesis have been shown to be mediated by PDGF.24 25
PDGF B gene expression may promote both smooth muscle cell proliferation and migration in this animal model. Experimental studies in rats indicate a role for PDGF BB in smooth muscle cell migration after balloon injury. The intima of the normal rat carotid artery does not contain smooth muscle cells, but within 7 days after balloon injury, an intima develops that is composed of smooth muscle cells that have migrated from the media into the intima.26 27 Infusion of recombinant PDGF BB protein into balloon-denuded carotid arteries resulted in an increase in medial smooth muscle cell replication and migration of smooth muscle cells from the media into the intima.5 Likewise, treatment of nude rats subjected to balloon injury of the carotid artery with high doses of a PDGF antibody resulted in a reduction in intimal thickening but no change in thymidine labeling,10 suggesting that a predominant effect of PDGF BB in these arteries is migration of medial smooth muscle cells. Furthermore, recent studies suggest that PDGF BB induces migration and proliferation via different signaling pathways.28
Determination of the role of PDGF BB in migration and proliferation in peripheral porcine arteries is complex, since the intima of normal porcine arteries contains rare, scattered smooth muscle cells.29 30 Direct measurement of smooth muscle cell migration is not possible, since the intima already contains smooth muscle cells; furthermore, we currently lack a method to label medial smooth muscle cells that may be responsive to autocrine or paracrine PDGF. Several lines of evidence suggest a possible role for PDGF Binduced migration in this study. We observed a greater number of smooth muscle cells in the intima of PDGF B arteries at 2 to 7 days than predicted from proliferation indexes, suggesting that migration may account for the increase in intimal cell number. Medial cells near the internal elastic lamina express hpAP and PDGF BB after gene transfer, and these PDGF BB cells are proliferating, as shown in double-labeling studies. However, regardless of the methods of statistical analysis, strong statements regarding mechanism cannot be made on the basis of correlation. Unfortunately, current methodology places some limitations on mechanistic studies, and inferential conclusions must be drawn.
The PDGF B/c-sis gene has been identified as the human homologue of the v-sis gene that was expressed in porcine arteries in this study. v-sis is a 271amino acid protein encoded by an open reading frame within the simian sarcoma virus genome. Residues 1 through 51 are derived from the env portions of the open reading frame, whereas residues 52 through 271 are highly homologous (96%) to the PDGF B/c-sis gene product.12 13 The primers used for PCR analysis were specific for v-sis sequence and not porcine PDGF, and hence, it is unlikely that endogenous porcine PDGF was detected in the PCR. However, although we cannot exclude the possibility that expression of v-sis indirectly induced expression of porcine PDGF B/c-sis, we know of no data to suggest direct cross-induction between v-sis and c-sis. Hence, the findings are attributable to v-sis expression, although we cannot exclude coexpression of endogenous porcine c-sis.
Cell proliferation in the intima declined after 7 days, while the intima continued to expand. Synthesis of extracellular matrix protein was observed between 1 and 3 weeks and is likely to contribute to continued growth of the intima. Cell proliferation decreased despite continued expression of the recombinant PDGF B gene, suggesting endogenous regulation of gene expression. It is possible that extracellular matrix or other factors within the artery may negatively regulate smooth muscle cell proliferation, including TGF-ß or other cofactors, and that these factors may counterbalance any direct effects of the PDGF B transgene on intimal smooth muscle cells. Few inflammatory cells, including macrophages and T cells, were observed in PDGF B arteries. These findings suggest that PDGF B gene expression, in the absence of balloon injury or hyperlipidemia, is not associated with recruitment of macrophages and T cells. In addition, it is unlikely that macrophages contributed a majority of PDGF BB in these nonatherosclerotic arteries. Taken together, these studies suggest a direct role for PDGF in the regulation of smooth muscle cell growth and repair in porcine arteries and provide a model in which PDGF ligand and receptor antagonists can be tested to dissect how the different forms of PDGF function in vivo.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received June 19, 1995; accepted October 4, 1995.
| References |
|---|
|
|
|---|
2. Libby P, Warner SJ, Salomon RN, Birinyi LK. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N Engl J Med. 1988;318:1493-1498. [Abstract]
3. Wilcox JN, Smith KM, Williams LT, Schwartz SM, Gordon D. Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest. 1988;82:1134-1143.
4.
Ross R, Glomset J, Kariya B, Harker L. A
platelet-dependent serum factor that stimulates the
proliferation of arterial smooth muscle cells in
vitro. Proc Natl Acad Sci U S A. 1974;71:1207-1210.
5. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89:507-511.
6.
Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox
JN, Schwartz SM. PDGF ligand and receptor gene expression during
repair of arterial injury. J Cell
Biol. 1990;111:2149-2158.
7.
Ross RJ, Masuda J, Raines EW, Gown AM, Katsuda S,
Sasahara M, Malden LT, Masuko H, Sato H. Localization of PDGF-B
protein in macrophages in all phases of atherogenesis.
Science. 1990;248:1009-1012.
8. Golden MA. Platelet-derived growth factor activity and mRNA expression in healing vascular grafts in baboons: association in vivo of platelet-derived growth factor mRNA and protein with cellular proliferation. J Clin Invest. 1991;87:406-414.
9. Nabel EG, Yang Z, Liptay S, San H, Gordon D, Haudenschild CC, Nabel GJ. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo. J Clin Invest. 1993;91:1822-1829.
10.
Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA,
Ross R. Inhibition of neointimal smooth muscle
accumulation after angioplasty by an antibody to PDGF.
Science. 1991;253:1129-1132.
11. Lusky M, Botchan M. Inhibition of SV40 replication in simian cells by specific pBR322DNA sequences. Nature. 1981;293:79-81. [Medline] [Order article via Infotrieve]
12.
Doolittle RF, Hunkapiller MW, Hood LE, Devare SG,
Robbins KC, Aaronson SA, Antoniades HN. Simian sarcoma
virus onc gene, v-sis, is derived from
the gene (or genes) encoding a platelet-derived growth factor.
Science. 1983;221:275-277.
13. Robbins KC, Aaronson SA. The sis oncogene. In: Reddy EP, Skalka AM, Curran T, eds. The Oncogene Handbook. Amsterdam, Netherlands: Elsevier Science Publishers; 1988.
14.
Henthorn PS, Knoll BJ, Raducha M, Rothblum KN,
Slaughter C, Weiss M, Lafferty MA, Fischer T, Harris H.
Products of two common alleles at the locus for human placental
alkaline phosphatase differ by seven amino acids. Proc
Natl Acad Sci U S A. 1986;83:5597-5601.
15.
Gorman CM, Merlino GT, Willingham MC, Pastan I, Howard
BH. The Rous sarcoma virus long terminal repeat is a strong
promoter when introduced into a variety of eukaryotic cells
by DNA-mediated transfection. Proc Natl Acad Sci
U S A. 1982;79:6777-6781.
16.
Muller DWM, Gordon D, San H, Yang ZY, Pompili VJ, Nabel
GJ, Nabel EG. Catheter-mediated pulmonary vascular
gene transfer and expression. Circ Res. 1994;75:1039-1049.
17. Nabel EG, Gordon D, Yang ZY, Xu L, San H, Plautz GE, Wu BY, Gao X, Huang L, Nabel GJ. Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther. 1992;3:649-656. [Medline] [Order article via Infotrieve]
18.
Nabel EG, Plautz G, Nabel GJ. Site-specific
gene expression in vivo by direct gene transfer into the
arterial wall. Science. 1990;249:1285-1288.
19. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Springs Harbor, NY: Cold Springs Harbor Press; 1989.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction. Anal Biochem. 1987;162:156-159. [Medline] [Order article via Infotrieve]
21. Schwartz RS, Chu A, Jeong MH, Staab ME, Srivatsa SS, Pompili VJ, Holmes DR. Vascular cell proliferation dynamics: implications for gene transfer and restenosis. In: March KL, ed. Gene Transfer and Cardiovascular Biology: Experimental Approaches and Therapeutic Implications. Norwell, Mass: Kluwer Press; 1996.
22. Winer BJ. Statistical Principles in Experimental Design. New York, NY: McGraw-Hill; 1971.
23. Dunnett CW. New tables for multiple comparisons with a control. Biometrics. 1964;20:482-494.
24. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-ß induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990;63:515-524. [Medline] [Order article via Infotrieve]
25.
Majack RA, Majesky MW, Goodman LV. Role of
PDGF-A expression in the control of vascular smooth muscle cell growth
by transforming growth factor-ß. J Cell
Biol. 1990;111:239-247.
26. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333. [Medline] [Order article via Infotrieve]
27. Reidy MA, Schwartz SM. Endothelial regeneration, III: time course of intimal changes after small defined injury to rat aortic endothelium. Lab Invest. 1981;44:301-308. [Medline] [Order article via Infotrieve]
28. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-1 and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 1994;93:1266-1274.
29. French JE, Jennings MA, Florey HW. Morphological studies on atherosclerosis in swine. Ann N Y Acad Sci. 1965;127:780-794. [Medline] [Order article via Infotrieve]
30. Luginbuhl HL, Jones JET. The morphology and morphogenesis of atherosclerosis in aged swine. Ann N Y Acad Sci. 1965;127:763-779. [Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
A. P. Lillis, L. B. Van Duyn, J. E. Murphy-Ullrich, and D. K. Strickland LDL Receptor-Related Protein 1: Unique Tissue-Specific Functions Revealed by Selective Gene Knockout Studies Physiol Rev, July 1, 2008; 88(3): 887 - 918. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Chen, F. Y. Lee, K. N. Bhalla, and J. Wu Potent Inhibition of Platelet-Derived Growth Factor-Induced Responses in Vascular Smooth Muscle Cells by BMS-354825 (Dasatinib) Mol. Pharmacol., May 1, 2006; 69(5): 1527 - 1533. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhan, S. Kim, Y. Izumi, Y. Izumiya, T. Nakao, H. Miyazaki, and H. Iwao Role of JNK, p38, and ERK in Platelet-Derived Growth Factor-Induced Vascular Proliferation, Migration, and Gene Expression Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 795 - 801. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Taylor and L. M. Khachigian Induction of Platelet-derived Growth Factor B-chain Expression by Transforming Growth Factor-beta Involves Transactivation by Smads J. Biol. Chem., May 26, 2000; 275(22): 16709 - 16716. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Rafty and L. M. Khachigian Novel Negative Regulatory Element in the Platelet-derived Growth Factor B Chain Promoter That Mediates ERK-dependent Transcriptional Repression J. Biol. Chem., April 6, 2000; 275(15): 11478 - 11483. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sjoland, D. T. Eitzman, D. Gordon, R. Westrick, E. G. Nabel, and D. Ginsburg Atherosclerosis Progression in LDL Receptor-Deficient and Apolipoprotein E-Deficient Mice Is Independent of Genetic Alterations in Plasminogen Activator Inhibitor-1 Arterioscler. Thromb. Vasc. Biol., March 1, 2000; 20(3): 846 - 852. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Heldin and B. Westermark Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor Physiol Rev, October 1, 1999; 79(4): 1283 - 1316. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Rekhter Collagen synthesis in atherosclerosis: too much and not enough Cardiovasc Res, February 1, 1999; 41(2): 376 - 384. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Rafty and L. M. Khachigian Zinc Finger Transcription Factors Mediate High Constitutive Platelet-derived Growth Factor-B Expression in Smooth Muscle Cells Derived from Aortae of Newborn Rats J. Biol. Chem., March 6, 1998; 273(10): 5758 - 5764. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |